Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.

Pharmacotherapy - 1 Feb 2010

Bai Jane P F, Lesko Lawrence J, Burckart Gilbert J

Abstract excerpt

The calcineurin inhibitors-cyclosporine and tacrolimus-are the mainstay of immunosuppressive therapy in solid organ transplantation. These drugs produce severe adverse drug effects (ADEs) such as nephrotoxicity, posttransplantation diabetes mellitus, and hypertension. Accumulated evidence suggest...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Calcineurin Inhibitors
Share to Cyclosporine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Immunosuppressive Agents

Share to Precision Medicine

Share to Renal Insufficiency

Share to Tacrolimus

Source

Identifiers

PMID: 20099993
DOI: 10.1592/phco.30.2.195

Genes

PPARG
VDR
ABCC8
ACE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20099993-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.PMID 20099993Read ↗

Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients.Semantic proximity Read ↗

The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity.Semantic proximity Read ↗

Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipientsSemantic proximity Read ↗

Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.Semantic proximity Read ↗

The genetics of kidney transplantation.Semantic proximity Read ↗

The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.Semantic proximity Read ↗

Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.Semantic proximity Read ↗

Tacrolimus-induced nephrotoxicity and genetic variability: a review.Semantic proximity Read ↗

Genetic prediction of renal transplant outcomeSemantic proximity Read ↗

Trends in Precision Medicine and Pharmacogenetics as an Adjuvant in Establishing a Correct Immunosuppressive Therapy for Kidney Transplant: An Up-to-Date Historical OverviewSemantic proximity Read ↗

Association of four DNA polymorphisms with acute rejection after kidney transplantation.Semantic proximity Read ↗

The Pharmacogenetics of Calcineurin Inhibitors: One Step Closer Toward Individualized Immunosuppression?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.